This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that five presentations describing the investigation of methylnaltrexone bromide as a potential treatment for opioid-induced constipation in adult patients with chronic, non-cancer pain will occur during The National Conference on Pain for Frontline Practitioners, or “PAINWeek”. PAINWeek is being held in Las Vegas, NV, Wednesday, Sept. 5 – Saturday, Sept. 8.
RELISTOR® (methylnaltrexone bromide) injection for subcutaneous use
Rauck et al. “Cardiac Safety of Subcutaneous Methylnaltrexone: Results from a Pooled Safety Analysis and a Case-Controlled Analysis in Noncancer Pain Patients with Opioid-Induced Constipation”
Methylnaltrexone bromide for oral use
Pepin et al. “Efficacy and Safety of Daily and As Needed Dosing of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain”
Rauck et al. “Cardiac Safety of Oral Methylnaltrexone in Healthy Subjects and Noncancer Pain Patients with Opioid-Induced Constipation”
Rauck et al. “Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Noncancer Pain”
Slatkin et al. “Safety and Tolerability of Oral Methylnaltrexone in Chronic Noncancer Pain Patients with Opioid-Induced Constipation”
About RELISTOR (methylnaltrexone bromide), Opioids and Constipation
Opioid analgesics are frequently prescribed for patients with chronic pain. Constipation, a common side effect, occurs in patients receiving opioid therapy. RELISTOR is the first approved medication that specifically targets the underlying cause of opioid-induced constipation in advanced illness patients when laxatives are insufficient. Opioids relieve pain by specifically interacting with mu–opioid receptors within the brain and spinal cord. However, opioids also interact with mu–opioid receptors found outside the central nervous system, such as those within the gastrointestinal tract, resulting in constipation that can be debilitating. RELISTOR is a peripherally acting mu–opioid receptor antagonist that does not cross the blood-brain barrier and was specifically designed to block mu-opioid receptors in the GI tract, therefore decreasing the constipating effects of opioid pain medications without affecting their ability to relieve pain.